7 medtech stories we missed this week: Sept. 22, 2017
[Image from unsplash.com]From the FDA’s clearance of Covalon’s film-drape to Bioventus launching its study, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears Covalon’s MediClear OTC surgical film-drape Covalon announced in a Sept. 21 press release that the FDA has cleared its MediClear PreOp to market in U.S. hospitals, clinic and directly to patients without a prescription. The MediClear PreOp is a breathable, transparent, self-adhesive, silicone barrier film-drape that can conform to a patient’s skin at a planned incision or insertion site. The film-drape helps protect the patient from bacteria, yeast and viruses. It can be applied by the patient or by clinicians at a consultation prior to surgical procedures. It is then removed immediately before surgery by a clinician in the operating room under sterile conditions. 2. ManaMed launches PlasmaFlow deep vein thrombosis prevention system ManaMed has launched the first FDA-approved digital and tubeless deep vein thrombosis prevention device, according to a Sept. 21 press release. The deep vein thrombosis prevention device, known as PlasmaFlow, is now available to medical practitioners in the U.S. PlasmaFlow is portable and tubeless with multiple pressure functions. It features a one-button operation, soft cuffs made of a high-grade medical material, 10 hours of rechargeable battery life and two LCD screen with a timer and pressure. I...
We report here the first successful transcatheter implantation of a stented valve in a pulmonary position in a dog with congenital pulmonary valve disease. A 3-year-old, 10.9 kg, client-owned Beagle dog was referred for a follow-up visit after a percutaneous balloon valvuloplasty performed 22 months before for treatment of a severe type A valvular pulmonary stenosis. The Doppler-derived peak pressure gradient (PG) was 348 mmHg before the procedure and 66 mmHg 24 hours after. The dog was lethargic. Echocardiography revealed a mild pulmonary stenosis (PG - 43 mmHg), severe pulmonary regurgitation, and secondary severe right ...
CONCLUSIONS: In young patients without risk factors developing a deep venous thrombosis, an inferior vena cava anomaly should be considered. Although no therapeutic consensus has been currently established, inferior vena cava agenesis seems to be associated with a high prevalence of thrombophilic disorders. Screening could be useful, particularly in patients with a thrombotic family history. PMID: 31611029 [PubMed - as supplied by publisher]
Authors: Quéré I, Galanaud JP, Sanchez O, pour le groupe de travail Recommandations de bonne pratique pour la prise en charge de la MVTE PMID: 31611025 [PubMed - as supplied by publisher]
Publication date: November 2019Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders, Volume 7, Issue 6Author(s): T.A. Miano, G. Abelian, M.J. Seamon, K. Chreiman, P.M. Reilly, N.D. Martin
Publication date: November 2019Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders, Volume 7, Issue 6Author(s): S. Salim, M. Zarrouk, J. Elf, A. Gottsäter, S. Sveinsdottir, P. Svensson
Publication date: November 2019Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders, Volume 7, Issue 6Author(s): M. Djulbegovic, A.I. Lee, K. Chen
Publication date: November 2019Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders, Volume 7, Issue 6Author(s): Cees H.A. Wittens, Stephen A. Black
Publication date: November–December 2019Source: Journal of Minimally Invasive Gynecology, Volume 26, Issue 7, SupplementAuthor(s): T Guo, C Liu, Z ZhangStudy ObjectiveThe aim of this study was to examine the applicability of the Caprini risk assessment model and gynecologic Caprini risk assessment model for postoperative venous thromboembolism risk assessment in gynecologic surgical patients and make a comparison between the two risk assessment models.DesignA database of a randomized controlled trial was employed. Scores of Caprini and gynecologic Caprini risk assessment model were calculated for each patient. Patien...
Authors: Grover SP, Mackman N Abstract The ferric chloride models of arterial thrombosis are useful tools with which to investigate the cellular and molecular mechanisms that contribute to arterial thrombosis. Recent insights have, however, revealed the complex and multifaceted mechanism by which ferric chloride induces thrombus formation. Here, we discuss the strengths and weaknesses of the ferric chloride models of arterial thrombosis. Particular focus is given to the phenotypes of different knockout mice in the ferric chloride models and how these compare to other models with independent modes of initiation. Fur...
We present a challenging case of recurrent acute coronary syndrome, in the context of very high thrombotic risk due to concomitant inflammatory disease. Although no general guidelines exist for the switch between antiplatelet agents, particularly in the acute setting, in specific cases, the availability of different orally- and i.v.-acting agents and platelet function tests may allow to discriminate among multiple possible mechanisms of drug failure or side effects in the individual patient. PMID: 31607192 [PubMed - as supplied by publisher]
More News: Angioplasty | Austria Health | Baloon Angioplasty | Belgium Health | Carotid Angioplasty | France Health | Germany Health | Hospitals | Laboratory Medicine | Medical Devices | Men | Nanotechnology | Netherlands Health | PET Scan | Portugal Health | Skin | Spain Health | Study | Thrombosis | Ultrasound